The Immunisation Handbook 2017 (the Handbook) provides clinical guidelines for health professionals on the safest and most effective use of vaccines in their practice. These guidelines are based on the best scientific evidence available at the time of publication, from published and unpublished literature.
Read the handbook
To read the Immunisation Handbook you can:
- view the Immunisation Handbook online
- download a PDF of the Immunisation Handbook (PDF, 6.7 MB)
- download an ebook version of the Immunisation Handbook (epub, 1.8 MB)
- download individual chapters of the Immunisation Handbook below.
Refer to the Pharmaceutical Schedule (on the Pharmac website) for the number of funded doses, eligibility criteria and any subsequent changes to the funding decisions.
Immunisation Handbook 2017 (2nd edition) – March 2018
The electronic Handbook has been updated, and a new edition published: Immunisation Handbook 2017 (2nd edition).
Major changes, in chapter order, are:
- Chapter 4 Immunisation of Special Groups: updated to include the herpes zoster vaccine funding from 1 April 2018, and new information about immune checkpoint inhibitors
- Chapter 8 Hepatitis B – includes information about the temporary brand change of the single antigen hepatitis B vaccine (from HBvaxPRO to Engerix-B)
- Chapter 10 Influenza – includes the change from trivalent to quadrivalent influenza vaccine (Fluarix Tetra and Influvac Tetra) and new information about immune checkpoint inhibitors
- Chapter 13 Mumps – updated to align with the latest version of the ‘Mumps’ chapter of the Communicable Disease Control Manual 2012
- Chapter 14 Pertussis – updated to align with the latest version of the ‘Pertussis’ chapter of the Communicable Disease Control Manual 2012
- Chapter 22 Zoster – updated to reflect the herpes zoster vaccine funding from 1 April 2018.
Detailed changes are described in Changes to the Immunisation Handbook 2017 (2nd edition) (PDF, 459 KB).
From 1 July 2020 the following changes are:
- PCV10 pneumococcal primary vaccination schedule changes from three doses plus a booster to a two dose plus booster schedule given at 6 weeks and 5 months with a booster at 15 months. The PCV13 vaccinations for those at high risk will continue to be given at 6 weeks, 3, 5, and 15 months
- Tdap replaces the funded Td for those aged 45 years who have not had four previous had four tetanus-containing vaccines in their lifetime and for those aged 65 years. Tdap will also replace the Td given for tetanus-prone wounds.
- Introduction (PDF, 307 KB)
- 1. General immunisation principles (PDF, 225 KB)
- 2. Processes for safe immunisation (PDF, 924 KB)
- 3. Vaccination questions and addressing concerns (PDF, 287 KB)
- 4. Immunisation of special groups (PDF, 594 KB)
- 5. Diphtheria (PDF, 378 KB)
- 6. Haemophilus inﬂuenzae type b (Hib) disease (PDF, 181 KB)
- 7. Hepatitis A (PDF, 174 KB)
- 8. Hepatitis B (PDF, 416 KB)
- 9. Human papillomavirus (HPV) (PDF, 530 KB)
- 10. Inﬂuenza (PDF, 434 KB)
- 11. Measles (PDF, 234 KB)
- 12. Meningococcal disease (PDF, 432 KB)
- 13. Mumps (PDF, 143 KB)
- 14. Pertussis (whooping cough) (PDF, 512 KB)
- 15. Pneumococcal disease (PDF, 524 KB)
- 16. Poliomyelitis (PDF, 123 KB)
- 17. Rotavirus (PDF, 217 KB)
- 18. Rubella (PDF, 167 KB)
- 19. Tetanus (PDF, 283 KB)
- 20. Tuberculosis (PDF, 209 KB)
- 21. Varicella (chickenpox) (PDF, 283 KB)
- 22. Zoster (herpes zoster/shingles) (PDF, 304 KB)
- Appendix 1: The history of immunisation in New Zealand (PDF, 378 KB)
- Appendix 2: Planning immunisation catch-ups (PDF, 308 KB)
- Appendix 3: Immunisation standards for vaccinators and guidelines for organisations offering immunisation services (PDF, 267 KB)
- Appendix 4: Authorisation of vaccinators and criteria for pharmacist vaccinators (PDF, 184 KB)
- Appendix 5: Immunisation certiﬁcate (PDF, 65 KB)
- Appendix 6: Passive immunisation (PDF, 372 KB)
- Appendix 7: Vaccine presentation, preparation, disposal, and needle-stick recommendations (PDF, 224 KB)
- Appendix 8: High-incidence TB countries (PDF, 139 KB)
- Appendix 9: Websites (PDF, 80 KB)
- Funded vaccines for special groups (PDF, 195 KB)
- Anaphylaxis (PDF, 52 KB)
- National Immunisation Schedule (PDF, 125 KB)